Sup Fig. 1 Dose response effect of CNTF in OIR. The therapeutic potential of CNTF was tested for different doses ranging from 0.05ng to 500ng in six different treatment groups. All mice received intravitreal injections of rrCNTF at OIR P12. VO and NV area were quantified at OIR P17. Intravitreal injection of 500ng rrCNTF resulted in a significant decrease in NV but not VO (N=16 mice). Treatment with 0.05 to 250ng rrCNTF resulted in significant reductions in both NV and VO in all treatment groups (N (0.05ng) = 10 mice, N (0.5ng) = 12 mice, N (5ng) = 11 mice, N (50ng) = 14 mice, N (250ng) = 12 mice, N (500ng) = 16 mice, error bars SEM).
Sup Fig. 2 CNTF treatment does not alter VEGF expression. Mice were treated with intravitreal injection of 500ng (A), 50ng (B) or 0.5ng (C) rrCNTF at OIR P12 (N=4 mice per dose). VEGF-A isoforms and VEGF-R2 mRNA expression was analyzed 24h later at OIR P13 (B and C) and additionally at OIR P14 and P17 for the 500ng treatment group (A, N=4 mice per time point). No significant change in mRNA expression was found at any dose or time point.